ARC AAT

Drug Profile

ARC AAT

Alternative Names: ARC-AAT

Latest Information Update: 16 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arrowhead Research Corporation
  • Developer Arrowhead Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alpha 1-antitrypsin deficiency

Most Recent Events

  • 02 Dec 2016 Arrowhead Pharmaceuticals withdraws prior to enrolment a phase II trial in Alpha 1-antitrypsin deficiency in Sweden, Italy, Ireland and Canada (IV) (NCT02900183)
  • 29 Nov 2016 Discontinued - Phase-I for Alpha 1-antitrypsin deficiency in Australia, Germany, Netherlands and United Kingdom (IV) due to company shifting its focus on on the development of RNAi therapeutics utilising its subcutaneous (subQ) and extra-hepatic delivery systems
  • 29 Nov 2016 Discontinued - Phase-II for Alpha 1-antitrypsin deficiency in Sweden, Canada, Italy, Ireland (IV) due to company shifting its focus on on the development of RNAi therapeutics utilising its subcutaneous (subQ) and extra-hepatic delivery systems
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top